Crossmark

Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis

Crossref DOI link: https://doi.org/10.1016/j.medcle.2021.04.026

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aparisi, Álvaro

Catalá, Pablo

Amat-Santos, Ignacio J.

Marcos-Mangas, Marta

López-Otero, Diego

Veras, Carlos

López-Pais, Javier

Cabezón-Villalba, Gonzalo

Cacho Antonio, Carla Eugenia

Candela, Jordi

Antúnez-Muiños, Pablo

Gil, José Francisco

González Ferrero, Teba

Rojas, Gino

Pérez-Poza, Marta

Uribarri, Aitor

Otero-García, Oscar

García-Granja, Pablo Elpidio

Jiménez Ramos, Víctor

Revilla, Ana

Dueñas, Carlos

Gómez, Itzíar

González-Juanatey, José Ramón

San Román, J. Alberto
License Information

Text and Data Mining valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01
More Information

This article is maintained by: Elsevier

Article Title: Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2021.04.026

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2021.04.005

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.